BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27600596)

  • 1. The dopamine D3 receptor, a quarter century later.
    Sokoloff P; Le Foll B
    Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.
    Mugnaini M; Iavarone L; Cavallini P; Griffante C; Oliosi B; Savoia C; Beaver J; Rabiner EA; Micheli F; Heidbreder C; Andorn A; Merlo Pich E; Bani M
    Neuropsychopharmacology; 2013 Jan; 38(2):302-12. PubMed ID: 22968817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO.
    Boileau I; Nakajima S; Payer D
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1410-20. PubMed ID: 26141509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.
    Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M
    Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.
    Le Foll B; Collo G; Rabiner EA; Boileau I; Merlo Pich E; Sokoloff P
    Prog Brain Res; 2014; 211():255-75. PubMed ID: 24968784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats.
    Gál K; Gyertyán I
    Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
    Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.
    Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA
    Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.
    Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I
    Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology profile of F17464, a dopamine D
    Cosi C; Martel JC; Auclair AL; Collo G; Cavalleri L; Heusler P; Leriche L; Gaudoux F; Sokoloff P; Moser PC; Gatti-McArthur S
    Eur J Pharmacol; 2021 Jan; 890():173635. PubMed ID: 33065094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO.
    Payer D; Balasubramaniam G; Boileau I
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():4-8. PubMed ID: 23999545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
    McCormick PN; Wilson VS; Wilson AA; Remington GJ
    Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.
    Le Foll B; Di Ciano P
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1401-9. PubMed ID: 25266821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.